Canakinumab, an anti-inflammatory, was used in a trial involving more than 10,000 patients, all of whom have had a heart attack but had not been diagnosed with cancer.
They were treated with the drug, which is given by injection, once every three months and monitored for up to four years.
The study showed a 15% reduction in the risk of heart attacks and strokes and the number of cancer deaths cut by half.![]()
